IL-9 Rat mediates immune responses through interactions with the IL-9 receptor (IL-9R), composed of IL-9Rα and the common gamma chain (γc). Key roles include:
T Cells: Promotes Th9 differentiation and enhances IL-9-dependent T-cell proliferation .
Mast Cells/Basophils: Drives survival, proliferation, and cytokine production (e.g., histamine) in allergic responses .
B Cells: Supports immunoglobulin production and humoral immunity .
Regulatory T Cells (Tregs): Enhances suppressive activity via STAT3/STAT5 signaling .
IL-9 Rat activates the JAK-STAT cascade, with downstream effects on gene transcription:
ELISA Kits: Quantify IL-9 in serum, plasma, or supernatants (e.g., Invitrogen ERA34RB) .
Recombinant Proteins: Used in vitro to study Th9 differentiation, mast cell activation, and Treg modulation .
Allergic Lung Inflammation: IL-9 overexpression in transgenic mice induces airway hyperresponsiveness and eosinophilia .
Parasitic Infections: Enhances immunity to Trichuris muris but exacerbates Leishmania major susceptibility .
Asthma: IL-9 amplifies IL-13-dependent mucus production and airway remodeling .
Autoimmunity: Blocking IL-9 reduces symptoms in myasthenia gravis and experimental autoimmune encephalomyelitis (EAE) .
Cancer: Context-dependent roles necessitate targeted therapies (e.g., IL-9 inhibition in Hodgkin’s lymphoma vs. augmentation in melanoma) .
Expression System | Advantages | Limitations |
---|---|---|
E. coli | High yield, cost-effective | Lack of glycosylation |
NS0 Cells | Proper glycosylation, bioactive conformation | Higher production costs |
Ongoing research focuses on IL-9 Rat's dual roles in immunity and pathology, with emphasis on:
Rat Interleukin-9 (IL-9) is a 20-30 kDa secreted glycoprotein belonging to the IL-7/IL-9 family of hematopoietic cytokines . It is primarily produced by activated T helper 2 (Th2) lymphocytes and functions as a regulatory cytokine in various immunological processes . The rat IL-9 cDNA encodes a 144 amino acid precursor protein with an 18 amino acid signal peptide that is cleaved to form the mature cysteine-rich protein with a molecular mass of approximately 14 kDa, though the native protein is heavily glycosylated . The gene identifier for rat IL-9 is 116558 with the gene symbol Il9, and protein aliases include ILN, Interleukin, Interleukin9, and interleukin-9 .
While the search results do not provide extensive comparative data, they indicate similarities between rat and mouse IL-9. Like mouse IL-9, rat IL-9 appears to function in T-cell differentiation and immune regulation. Both species have IL-9 proteins that undergo post-translational modifications, particularly glycosylation, which affects their molecular weight and functional properties . Research indicates that findings on IL-9-secreting TH9 cells have antitumor properties in both mouse and human cancers, suggesting conserved functional roles across species .
The primary source of IL-9 in rats is activated T helper 2 (Th2) lymphocytes . More recently, a distinct subset of CD4+ T cells called TH9 cells has been identified as specialized producers of IL-9 . These cells differentiate from naive CD4 T cells when stimulated with transforming growth factor beta (TGF-β) and IL-4 . Additionally, research has shown that TGF-β can reprogram existing Th2 cells to secrete IL-9, effectively converting them to TH9 cells .
Several validated methods exist for detecting IL-9 in rat samples:
ELISA Assays: Rat IL-9 ELISA kits can quantitate IL-9 in rat serum, plasma, and cell culture supernatants . These assays recognize both natural and recombinant rat IL-9 with high specificity.
Flow Cytometry: Flow cytometric analysis using anti-rat IL-9 antibodies can detect intracellular IL-9 in rat cells. This typically requires cell fixation with paraformaldehyde and permeabilization with saponin . For optimal results, cells may need stimulation with agents such as PMA (phorbol 12-myristate 13-acetate) and calcium ionophore.
Reporter Systems: While not explicitly mentioned for rats, reporter systems like IL-9-GFP have been used in mouse models and could potentially be adapted for rat studies .
For flow cytometry detection of intracellular IL-9, rat splenocytes should be treated with appropriate stimulants (e.g., 50 ng/mL PMA and 500 ng/mL Ca2+ ionophore for 24 hours), followed by fixation with paraformaldehyde and permeabilization with saponin before staining with anti-IL-9 antibodies . For ELISA assays, sample preparation will depend on the specific kit instructions, but generally involves collection of serum, plasma, or cell culture supernatants under sterile conditions .
When conducting antibody-based detection methods such as flow cytometry, appropriate isotype controls are essential. For anti-rat IL-9 antibodies, a suitable control would be rat IgG1 isotype control (such as clone HRPN) . In neutralization experiments, including both the neutralizing antibody and appropriate isotype controls is critical for result interpretation . When using fluorescently labeled secondary antibodies, include controls with secondary antibody alone to account for non-specific binding .
IL-9 in rats serves several important immunoregulatory functions:
Regulates multiple cell types involved in Th2-associated asthma responses, including B and T lymphocytes, mast cells, eosinophils, and epithelial cells
Plays a critical role in the antitumor functions of TH9 cells, as demonstrated in adoptive transfer experiments
Contributes to TH9 cell-mediated immune responses, which are essential for the efficacy of certain cancer immunotherapy treatments such as dendritic cell vaccination and anti-GITR therapy
IL-9 production in rats is regulated by a complex network of cytokines and signaling pathways. TGF-β plays a particularly important role, reprogramming Th2 cells to secrete IL-9 and driving the differentiation of TH9 cells . The combination of TGF-β and IL-4 stimulates the differentiation of naive CD4 T cells into IL-9-producing TH9 cells . Proinflammatory factors, including IL-1β and tumor necrosis factor alpha (TNF-α), enhance TH9 differentiation and subsequent IL-9 production . Additionally, recent evidence suggests that STING (Stimulator of Interferon Genes) signaling may influence T cell differentiation and potentially IL-9 production, though the exact mechanism needs further investigation .
TH9 cells are specialized CD4+ T cells that produce high levels of IL-9 . These cells exert IL-9-mediated antitumor functions when adoptively transferred into tumor-bearing mice, suggesting IL-9 is the primary mediator of their anticancer activity . In experimental settings, TH9 cells stimulated with cyclic GMP-AMP synthase (cGAMP) before in vitro polarization showed enhanced antitumor efficacy when adoptively transferred into B16-OVA tumor-bearing mice . This indicates that manipulating TH9 cells can modulate IL-9 production and subsequent antitumor functions.
IL-9 regulates multiple cell types involved in Th2-associated asthma responses, including B and T lymphocytes, mast cells, eosinophils, and epithelial cells . While the search results don't provide specific experimental details for rat asthma models, the involvement of IL-9 in regulating these cell types suggests its importance in allergic airway inflammation. Understanding IL-9's role in these models can provide insights into potential therapeutic targets for asthma and allergic conditions.
IL-9, primarily through TH9 cells, demonstrates significant antitumor properties in experimental cancer models . When adoptively transferred into tumor-bearing mice, IL-9-secreting TH9 cells exert potent antitumor functions . The experimental protocol typically involves:
Establishing tumors (e.g., B16-OVA melanoma) in mice
Generating and potentially manipulating TH9 cells in vitro
Adoptively transferring 2×10^6 effector TH9 cells intravenously
Monitoring tumor growth by measuring tumor dimensions three times weekly
In lung metastasis models, 2.5×10^5 B16-OVA cells are injected intravenously, followed by TH9 cell transfer one day later, with lung tumor foci enumerated 14 days post-transfer .
The following protocol outlines a method for using IL-9-producing TH9 cells in adoptive transfer experiments:
Generate effector TH9 cells from naive CD4 T cells (e.g., from OT-II transgenic mice) by stimulating with TGF-β and IL-4
Optionally stimulate cells with cGAMP or other agents before in vitro polarization to enhance their function
Inject 2×10^6 effector TH9 cells intravenously into tumor-bearing recipients (typically 5 days after subcutaneous tumor implantation)
Monitor tumor growth by measuring dimensions three times weekly, euthanizing mice when tumors exceed 300 mm^2 or become ulcerated
For intravenous tumor models, inject tumor cells first, followed by TH9 cell transfer one day later, and evaluate outcomes after 14 days .
While the search results don't provide rat-specific protocols, neutralizing antibodies against IL-9 can be used with appropriate isotype controls, such as rat IgG1 isotype control (clone HRPN, BioXCell) . When designing neutralization experiments, consider:
Determining appropriate antibody dosage through dose-response studies
Including proper isotype controls at equivalent concentrations
Validating neutralization efficiency through functional assays
Administering antibodies at time points relevant to the experimental question
The effectiveness of neutralization should be verified through downstream measurements of IL-9-dependent activities.
Recent research highlights the importance of STING (Stimulator of Interferon Genes) signaling in T cell differentiation and function . When studying IL-9 in relation to STING signaling, several factors should be considered:
Use of appropriate genetic models, such as Sting1^-/- or STING V154M/WT mice, which could be adapted or compared to rat models
Investigation of how STING agonists like cGAMP affect TH9 cell differentiation and IL-9 production
Consideration of the interplay between STING, type I interferon signaling, and IL-9 production, potentially using Ifnar^-/- models
Assessment of how STING signaling affects the antitumor functions of IL-9-producing cells in vivo
When confronted with conflicting data on IL-9 functions, researchers should:
Carefully evaluate the experimental systems used, as IL-9 function may be context-dependent
Consider strain differences in rats, as genetic background can influence cytokine responses
Examine the specific cell types and activation conditions used, as these can dramatically affect IL-9 production and function
Assess the presence of other cytokines in the experimental system, as cytokine networks involve complex interactions
Compare in vitro versus in vivo results, recognizing that cell culture findings may not always translate to whole animal models
Verify antibody specificity and detection method sensitivity, as technical variations can lead to apparently conflicting results
Emerging areas in rat IL-9 research include:
Further exploration of the role of STING signaling in controlling TH9 cell differentiation and IL-9 production
Investigation of the mechanisms by which IL-9-producing cells mediate antitumor immunity and how this can be enhanced
Development of more sophisticated genetic models to study IL-9 function in vivo
Examination of IL-9's role in neuroinflammation and potential neuroimmune interactions
Exploration of IL-9 as a therapeutic target or agent in various disease contexts
While the search results don't directly address epigenetic regulation of IL-9, this represents an important frontier in cytokine research. Investigators might consider:
Examining histone modifications at the Il9 locus during TH9 cell differentiation
Investigating DNA methylation patterns that correlate with IL-9 expression
Studying the role of microRNAs in post-transcriptional regulation of IL-9
Exploring how environmental factors might induce epigenetic changes affecting IL-9 production
Comparing epigenetic signatures between different IL-9-producing cell populations
Findings from rat IL-9 research have several potential translational applications:
Development of IL-9-based or IL-9-targeting therapeutics for cancer immunotherapy, given the potent antitumor properties of IL-9-producing TH9 cells
Exploration of the essential role of IL-9 in the efficacy of dendritic cell vaccination and anti-GITR therapy, suggesting combination approaches for enhanced cancer treatment
Investigation of IL-9 manipulation for allergic and inflammatory conditions, given its role in regulating cells involved in asthma responses
Consideration of the TGF-β/IL-9 axis as a therapeutic target in various disease contexts
IL-9 is a member of the type I cytokine receptor family. The IL-9 receptor (IL-9R) is a protein that specifically mediates the biological effects of IL-9. The receptor is composed of two subunits: the IL-9R alpha subunit and the common gamma chain (γc). The binding of IL-9 to its receptor leads to the activation of various signaling pathways, including the JAK/STAT pathway, which is crucial for transmitting signals from the cell surface to the nucleus .
Recombinant IL-9 refers to IL-9 that is produced through recombinant DNA technology. This involves inserting the gene encoding IL-9 into a host cell, such as bacteria or yeast, which then produces the cytokine. Recombinant IL-9 is used in research to study its effects on various cell types and to understand its role in diseases such as asthma and allergies .
Recombinant rat IL-9 is particularly useful in research involving rodent models. It is used to study the effects of IL-9 on rat immune cells and to investigate the potential therapeutic applications of IL-9 in treating diseases. For example, recombinant rat IL-9 can be used to study its role in mast cell maturation and the enhancement of IgE production by B cells .